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Abstract
Background: While children and young adults had the highest attack rates due to 2009 pandemic (H1N1) influenza A (2009
H1N1), studies of hospitalized cases noted high fatality in older adults. We analyzed California public health surveillance
data to better characterize the populations at risk for dying due to 2009 H1N1.
Methods and Findings: A case was an adult $20 years who died with influenza-like symptoms and laboratory results
indicative of 2009 H1N1. Demographic and clinical data were abstracted from medical records using a standardized case
report form. From April 3, 2009 – August 10, 2010, 541 fatal cases $20 years with 2009 H1N1 were reported. Influenza
fatality rates per 100,000 population were highest in persons 50–59 years (3.5; annualized rate=2.6) and 60–69 years (2.3;
annualized rate=1.7) compared to younger and older age groups (0.4–1.9; annualized rates=0.3–1.4). Of 486 cases
hospitalized prior to death, 441 (91%) required intensive care unit (ICU) admission. ICU admission rates per 100,000
population were highest in adults 50–59 years (8.6). ICU case-fatality ratios among adults ranged from 24–42%, with the
highest ratios in persons 70–79 years. A total of 425 (80%) cases had co-morbid conditions associated with severe seasonal
influenza. The prevalence of most co-morbid conditions increased with increasing age, but obesity, pregnancy and
obstructive sleep apnea decreased with age. Rapid testing was positive in 97 (35%) of 276 tested. Of 482 cases with
available data, 384 (80%) received antiviral treatment, including 49 (15%) of 328 within 48 hours of symptom onset.
Conclusions: Adults aged 50–59 years had the highest fatality due to 2009 H1N1; older adults may have been spared due to
pre-existing immunity. However, once infected and hospitalized in intensive care, case-fatality ratios were high for all adults,
especially in those over 60 years. Vaccination of adults older than 50 years should be encouraged.
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Introduction
The 2009 pandemic (H1N1) influenza A virus (2009 H1N1)
emerged in April 2009 to cause a global pandemic that lasted 16
months [1]. The highest attack rates were reported among
children and young adults; 60% of laboratory-confirmed infections
and 32–45% of hospitalized cases in the United States occurred in
persons under 18 years of age, and cases younger than 65 years
accounted for approximately 90% of deaths [1]. These prelimi-
nary data led to initial ACIP recommendations in July 2009 to
target limited initial supplies of H1N1 vaccine to persons younger
than age 65 years [2]; these recommendations have since been
updated [3].
In April 2009 the California Department of Public Health
(CDPH) initiated surveillance for hospitalized and fatal cases of
2009 H1N1 infection. Our early review of the first 16 weeks of the
pandemic suggested that while most hospitalized cases were
young, the case-fatality ratio among hospitalized cases was highest
in those aged 50 years or older [4]. In this report, we expand on
our previous findings to review the epidemiologic and clinical
characteristics of adult Californians who died due to 2009 H1N1
throughout the pandemic.
Materials and Methods
Ethics Statement
During the period of this study 2009 H1N1 infection was a
reportable disease in California. This activity was reviewed and
determined by the California Committee for the Protection of
Human Subjects to be consistent with an emergent public health
response that did not require institutional review board approval.
A case was an adult $20 years of age who died with clinical
illness consistent with respiratory infection and had results from
testing of a respiratory specimen that were indicative of 2009
H1N1 influenza by a reverse-transcriptase polymerase chain
reaction assay developed by the Centers for Disease Control and
Prevention and authorized by the FDA (http://www.cdc.gov/
h1n1flu/guidance/rapid_testing.htm). During April 3 - August 11,
2009, state recommendations for laboratory testing as well as case-
based reporting was performed for all Californians who were
hospitalized or died with 2009 H1N1 infection. After August 11,
2009, state recommendations for laboratory testing and case-based
reporting were limited to Californians with 2009 H1N1 infection
who required intensive care unit (ICU) admission or died.
Hospitalized and fatal cases were reported by providers and
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of hospitals were reported by county coroners to the local health
department. Cause of death was determined by review of death
certificates by the reporting clinician or local health department.
All cases were subsequently reported from local health depart-
ments to CDPH. For both hospitalized and fatal cases, data on
demographics, including race/ethnicity, clinical presentation and
course, co-morbid conditions, and laboratory and radiographic
findings were abstracted from medical records, and autopsy
reports where appropriate, by staff at the local health department
or CDPH using the same standardized case report form. Body
mass index (BMI) was calculated from available height and weight
data as body weight in kilograms divided by the square of height in
meters. Adult obesity was defined in accordance with the National
Institutes of Health (NIH) classification [5]. Among reported cases
with BMI data, we analyzed: NIH BMI categories of 30–39 (obese)
and $40 (extreme obesity) [5]. Co-morbidities were considered
absent in cases where records stated that the patient was previously
healthy or had no underlying medical conditions; likewise, only the
454 cases with available height and weight data were included in
the analysis of BMI and association with age.
Population-based fatality rates were calculated by age group
using all reported influenza deaths, and were defined as number
of fatal cases per 100,000 population. Case-fatality ratios were
calculated using reported deaths that had been admitted to the
ICU and were defined as (number of fatal ICU cases from age
group/total number of ICU cases within that age group)*100.
Distributions of demographic and clinical risk factors among age
groups were also analyzed. Significant trends among different age
groups were calculated using the Cochran-Armitage trend test.
For the trend analysis, the denominators used for extreme obesity
(BMI $40) and obesity (BMI 30–39) were 454 (all cases with
height and weight data available) and 356, respectively; in the
latter, extremely obese cases (n=98) were excluded in order to
assess any association between age and the presence of obesity
(BMI 30–39) as compared to the absence of obesity (BMI,30).
All analyses were performed using SAS 9.2 (SAS Institute, Cary,
NC).
Results
Case fatality rates
Between April 3, 2009 – August 10, 2010, 541 fatal cases of
2009 H1N1 in adults $20 years of age were reported. Table 1
presents data on ICU admission and mortality by age group, and
includes age groups under 20 years for comparison. Influenza
fatality rates were highest in persons 50–59 years (3.5; annualized
rate 2.6) and 60–69 years (2.3; annualized rate 1.7) and lower (0.4–
1.9; annualized rates 0.3–1.4) in younger and older age groups.
ICU admission rates per 100,000 population were highest in adults
50–59 years of age (8.6). Case-fatality ratios in adults ranged from
24–42%, with the highest ratio in persons 70–79 years.
To identify if there was any temporal variation in mortality,
influenza fatality rates and case-fatality ratios were calculated for
two separate time periods that corresponded to two waves of 2009
H1N1 activity: April 3-October 3, 2009, and October 4, 2009-
February 4, 2010 (Figure 1). The influenza fatality rate remained
highest for 50–59 year-olds during both time periods: 1.1 (range:
0.2–1.1; 0.6 for all ages) during the first wave, and 1.8 (range: 0.2–
1.8; 0.8 for all ages) during the second wave. Likewise, case-fatality
ratios were similarly high among adults admitted to the ICU
during both time periods.
Epidemiologic and clinical characteristics of fatal cases
Table S1 summarizes epidemiologic and clinical characteristics.
Of the 541 fatal cases $20 years of age, 267 (49%) were male. Of
519 fatal cases with available information, 224 (43%) were
Hispanic and 210 (40%) were non-Hispanic white.
The median time from onset of symptoms to death was 14 days
(range 0–131 days). Of the 541 fatalities, 486 (90%) were
hospitalized. 441 (91%) hospitalized cases required intensive care.
399 (95%) of 422 received mechanical ventilation.
Table 1. Total number of cases reported and fatality rate of 2009 H1N1 influenza in California, April 3, 2009 - August 10, 2010.
FATAL CASES ICU CASES
Age, y
Number of
fatal cases
Influenza fatality
rate per 100,000
population
a
Annual influenza fatality
rate per 100,000
population
a
Number of
cases admitted
to ICU
ICU admission rate
per 100,000
population
a
Number of fatal
cases admitted
to ICU
Case-fatality
ratio
b
,1 7 1.2 0.9 83 14.8 7 8.4%
1–9 21 0.4 0.3 284 5.8 18 6.3%
10–19 27 0.5 0.3 216 3.7 25 11.6%
20–29 77 1.4 1.1 268 4.9 64 23.9%
30–39 72 1.4 1.0 208 4.0 53 25.5%
40–49 108 1.9 1.4 283 4.9 89 31.4%
50–59 170 3.5 2.6 425 8.6 142 33.4%
60–69 72 2.3 1.7 164 5.2 62 37.8%
70–79 27 1.5 1.1 52 2.9 22 42.3%
80+ 15 1.2 0.9 25 2.1 9 36.0%
Total 596 1.5 1.2 2008 5.2 491 24.5%
Abbreviations: ICU, intensive care unit.
aRates were calculated using 2009 statewide age-specific population projections published by the State of California Department of Finance (URL: http://www.dof.ca.
gov/research/demographic/data/race-ethnic/2000-50/).
bExcludes non-hospitalized fatalities; the case-fatality ratio is calculated using the following formula: (number of fatal ICU cases from age group/total number of ICU
cases within that age group)*100.
doi:10.1371/journal.pone.0018221.t001
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tested positive. Sixty-nine (13%) had also microbiologic evidence
of secondary bacterial infection.
Of 482 cases where data were available, 384 (80%) received
antiviral treatment; the median time in days from onset to antiviral
treatment was 5 days (range: 0–47 days). Forty-nine (15%) of 328
received antiviral treatment within 48 hours of symptom onset.
Fifty-five adults died at home without hospitalization; of these,
32 (58%) had been seen as an outpatient prior to their death. Of
the 40 of 55 cases who had information available, nine (23%) had
received antiviral treatment prior to death. Dates of treatment
were available for eight of these cases; the median time from onset
of symptoms to treatment was 3 days (range 1–10 days), and three
(38%) had received treatment within 48 hours of symptom onset.
Co-morbid conditions associated by the Advisory
Committee on Immunization Practices (ACIP) with severe
influenza
Four hundred twenty-five (80%) had a co-morbid condition
associated by the ACIP with severe seasonal influenza infection (3);
the most common were chronic metabolic disease, primarily
diabetes mellitus and renal disease (215/531; 40%), chronic lung
disease (202/530; 38%), chronic cardiac disease (143/521; 27%),
immunosuppressive conditions, primarily neoplasms (133/529;
25%) and extreme obesity with a BMI $40 (98/454; 22%). Of 532
with available data, 364 (68%) fatal cases had other comorbidity
such as obesity [body mass index 30–39 (159/454;35%)] and
hypertension (208/529; 39%). There was no association between
the number of co-morbidities in each case and median time from
onset of symptoms to death.
Table S1 also demonstrates the distribution of co-morbid
illnesses and details of hospital course by age group. Older fatal
cases were significantly more likely than younger cases to have
ACIP-defined high risk conditions (p,0.001), including chronic
lung diseases (especially chronic obstructive pulmonary disease;
p,0.0001), chronic cardiac diseases (coronary artery disease,
congestive heart failure and arrythmias; p,0.0001), immunosup-
pression (mainly malignancy, solid organ transplant, or chronic
immunosuppressive drugs; p,0.0001), and chronic neurologic
diseases (history of cerebrovascular accident, Alzheimer’s disease,
Parkinson’s disease and dementia; p,0.05) (7). In patients younger
than 70 years, the prevalence of chronic metabolic diseases
(diabetes mellitus, p,0.0001; renal disease, p,0.05, and hypo-
thyroidism, p,0.05) and hyperlipidemia (p,0.0001) significantly
increased with age. Older fatal cases were also significantly more
likely than younger cases to have conditions not associated by the
ACIP with severe influenza, including chronic gastrointestinal
disease (p,0.0001) and hypertension (p,0.0001).
Conversely, the prevalence of certain ACIP-defined high risk
conditions significantly decreased with increasing age, including
extreme obesity (BMI $40) (p,0.0001), pregnancy (p,0.0001)
and obstructive sleep apnea (p,0.05). The prevalence of obesity
Figure 1. Fatal cases of 2009 pandemic (H1N1) influenza A in California by date of death. In California, mortality peaks due to 2009
pandemic (H1N1) influenza A coincided with two waves of 2009 H1N1 activity: April 3-October 3, 2009, and October 4, 2009-February 4, 2010. The
influenza fatality rate remained highest for 50–59 year-olds during both time periods.
doi:10.1371/journal.pone.0018221.g001
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significantly decreased with increasing age in persons older than
that age group (p=0.0007).
Discussion
We reviewed more than 500 fatal cases of 2009 H1N1 in
California to better characterize populations at risk. Persons aged
50–59 years had the highest influenza fatality rate. Over 90% of
fatal cases had co-morbid illnesses; 80% had a co-morbid
condition associated by the ACIP with severe seasonal influenza
infection [3]. Age groups older than 60 years of age had
progressively decreasing influenza fatality rates despite their
increasing prevalence of co-morbidity associated with severe
influenza; the most common co-morbidity in adults under age
60 was obesity. Although all adult age groups had high case-
fatality ratios once admitted to intensive care, persons 70–79 years
were most likely (42%) to die. While cases were ascertained from
passive reporting by clinicians, who may have underreported cases
due to under-recognition or limited access to confirmatory
laboratory testing, these limitations are unlikely to have introduced
any selection bias that would affect these findings.
Others have reported maximal case fatality rates in different age
groups. During the first wave of the pandemic the case fatality rate
in Mexico ranged from 3 to 13 per 100,000, with the highest rates
occurring in persons aged 20–49 years of age [6]. In the same
period adults aged 40–59 years in North, Central and South
America, Europe and Asia demonstrated the highest mortality at
0.54–0.57 per million population, compared to 0.40 per million
for all ages [7]. In England, public health surveillance data
collected over two pandemic waves found higher population
mortality rates in persons $65 years (9.3 per 1000) compared to
under 65 years (0.4 per 1000) [8]. Demography may have
contributed to these differences, as it is possible that higher attack
rates occurred in larger age segments of the population. The
variability in mortality by setting may also reflect differences in
ascertainment criteria, or testing and surveillance methods.
Additionally, susceptibility to severe infection may have varied
by age at different times during the pandemic as immunity spread
within a population. Our results are consistent with US national
data (which includes California), where cases aged 50–64 years
had the highest death rate (1.69 per 100,000, compared to 0.97 for
all age groups) (http://www.cdc.gov/H1N1flu/hosp_deaths_
ahdra.htm). Even with this variation, all studies have estimated
mortality rates due to 2009 H1N1 that are no higher than those
typically reported for seasonal influenza [3]; these rates are likely
underestimates due to underreporting.
With seasonal influenza, persons $65 years account for .95%
of deaths; those over 85 years are 32 times more likely to die than
persons aged 60–65 years [3]. The decline in 2009 H1N1 case-
fatality rates we observed in persons $60 years, despite an
increasing prevalence with age of ACIP-defined high risk
conditions, strongly suggests that pre-existing immunity provided
some protection. This immunity was likely derived from exposure
to antigenically-related H1N1 viruses that circulated between
emergence of the pandemic H1N1 influenza virus in 1918 and the
H2N2 virus in 1957 [9]. Serologic studies support this hypothesis:
one-third of those born in the US before 1950 had high titers
against 2009 H1N1 prior to 2009, compared to 4% of persons
born after 1980 [9]. Cross-protective antibody was found in 96%
of Finns born between 1909–1919, 14–77% born between1920–
1944, and few born after 1944 [10].
Regardless of pre-existing immunity, fatality of all adults
hospitalized in intensive care for 2009 H1N1 was high, including
in persons over 60 years. The vulnerability of the elderly to severe
illness from a newly emergent influenza virus should not be
underestimated. Experience with previous pandemics suggests that
the younger age bias observed for 2009 H1N1 may shift in coming
months to older persons. While half of influenza-related deaths
during the 1968-69 influenza A (H3N2) pandemic and a large
proportion of deaths during the 1957-58 influenza A (H2N2) and
the 1918–1919 influenza A (H1N1) pandemics occurred among
persons ,65 years of age, this group accounted for progressively
smaller proportions of deaths during the decade following each
pandemic [11–12]. These observations reinforce the importance of
routine vaccination of older age groups, who appear to respond
well to monovalent vaccination against 2009 H1N1 [13–14].
While the overall efficacy of vaccination in the elderly is uncertain,
one large randomized controlled trial found that vaccination for
seasonal influenza decreased the likelihood of hospitalization by
27% and death by 50% in the elderly residing in the community
[15].
We conclude with two major points: in contrast to seasonal
influenza, adults aged 50–59 years in California had the highest
fatality rate due to 2009 H1N1; adults over 60 years may have
been somewhat spared due to pre-existing relative immunity.
However, once infected and hospitalized in intensive care, case-
fatality ratios in California were high for all adults, especially the
elderly. When 2009 H1N1 is known to be circulating, clinicians
should maintain a high level of suspicion in persons of all ages
presenting with influenza-like illness, including middle aged and
elderly adults. Additionally, when novel pandemic influenza
viruses emerge and cause disease, immunization policies, partic-
ularly during shortages, should be flexible and consider the
changing demographic of those affected, including taking into
account those populations with high mortality rates.
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